I would agree that others here have greatly inflated the importance of this announcement (e.g ‘rockets’). However, in the context of the impending DSMB review at 60% and haziness around timing of the 60% review could be suggestive that the FDA might in the process of reviewing data for an EUA. I see this announcement as the first domino in the bureaucracy of FULL approval - even better than an EUA.
Fact check: Remestemcel-L was submitted under a BLA, not an NDA as it is a biologic.
I would agree that others here have greatly inflated the...
-
- There are more pages in this discussion • 464 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.055(5.16%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | $1.00 | $1.699M | 1.665M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 51382 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 40413 | 15 |
View Market Depth
| Last trade - 11.51am 04/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |